210 related articles for article (PubMed ID: 35342094)
61. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
[TBL] [Abstract][Full Text] [Related]
62. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.
Kresge HA; Liu D; Gupta DK; Moore EE; Osborn KE; Acosta LMY; Bell SP; Pechman KR; Gifford KA; Mendes LA; Wang TJ; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL
J Alzheimers Dis; 2020; 74(3):965-974. PubMed ID: 32144980
[TBL] [Abstract][Full Text] [Related]
63. Tau Pathologies Mediate the Association of Cigarette Smoking with Cognitive Impairment in Older Adults Without Dementia: The CABLE Study.
Hu H; Fu JT; Bi YL; Ma YH; Huang YY; Wang X; Tan L; Yu JT
J Alzheimers Dis; 2022; 86(4):1849-1859. PubMed ID: 35253762
[TBL] [Abstract][Full Text] [Related]
64. Characteristics of Subjective Cognitive Decline Associated with Alzheimer's Disease Amyloid Pathology: Findings from The CABLE Study.
Zhao YL; Ou YN; Ma YH; Tan L; Yu JT
J Alzheimers Dis; 2023; 92(2):581-590. PubMed ID: 36776070
[TBL] [Abstract][Full Text] [Related]
65. Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.
Hoscheidt SM; Starks EJ; Oh JM; Zetterberg H; Blennow K; Krause RA; Gleason CE; Puglielli L; Atwood CS; Carlsson CM; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016 Apr; 52(4):1373-83. PubMed ID: 27079723
[TBL] [Abstract][Full Text] [Related]
66. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
67. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
[TBL] [Abstract][Full Text] [Related]
68. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
[TBL] [Abstract][Full Text] [Related]
69. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
[TBL] [Abstract][Full Text] [Related]
70. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
71. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
72. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
[TBL] [Abstract][Full Text] [Related]
73. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
[TBL] [Abstract][Full Text] [Related]
74. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
75. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
[TBL] [Abstract][Full Text] [Related]
76. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
77. Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.
Khan TK; Alkon DL
J Alzheimers Dis; 2015; 46(4):817-36. PubMed ID: 26402622
[TBL] [Abstract][Full Text] [Related]
78. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.
Ott BR; Cohen RA; Gongvatana A; Okonkwo OC; Johanson CE; Stopa EG; Donahue JE; Silverberg GD;
J Alzheimers Dis; 2010; 20(2):647-57. PubMed ID: 20182051
[TBL] [Abstract][Full Text] [Related]
79. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.
Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M
J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972
[TBL] [Abstract][Full Text] [Related]
80. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]